Pharmaceutical Makers, Amway Change Strategy After SARS
Multinational makers operating in the China market are
changing their strategies for the post-SARS period. Most
companies are introducing new products in order to quickly
establish market share.
GlaxoSmithKline has changed its vaccine production and
sales plans, and has decided to step up production of
vaccines in China. Chinese government officials, on the
local and central government levels, are now adjusting
their public health policies to focus more on disease
prevention. This will increase the opportunities for sales
of vaccines in China.
Amway China has been another beneficiary of this new
attitude. Sales of Amway's health food and disinfectants
in China have skyrocketed, and in many places, there are
shortages of products. Amway is stepping up production
to relieve these shortages. Amway is also moving many
production facilities from outside China to China.
Because SARS has had an effect on face to face sales,
Amway has asked its China sales staff to contact buyers
by phone, and also to focus on repeat sales to previous
buyers.
Before you go, did you like this article?
If so, you can receive a free email newsletter version
each weekday. Sign up using the China Business Express
form on this page.
